Find in Library

The <i>RUNX1-RUNX1T1</i> fusion is a frequent chromosomal alteration in acute myeloid leukemias (AMLs). Although <i>RUNX1-RUNX1T1</i> fusion protein has pivotal roles in the development of AMLs with the fusion, <i>RUNX1-RUNX1T1</i>, fusion protein is difficult to target, as it lacks kinase activities. Here, we used bioinformatic tools to elucidate targetable signaling pathways in AMLs with <i>RUNX1-RUNX1T1</i> fusion. After analysis of 93 AML cases from The Cancer Genome Atlas (TCGA) database, we found expression of 293 genes that correlated to the expression of the <i>RUNX1-RUNX1T1</i> fusion gene. Based on these 293 genes, the cyclooxygenase (COX), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways were predicted to be specifically activated in AMLs with <i>RUNX1-RUNX1T1</i> fusion. Moreover, the in vitro proliferation of AML cells with <i>RUNX1-RUNX1T1</i> fusion decreased significantly more than that of AML cells without the fusion, when the pathways were inhibited pharmacologically. The results indicate that novel targetable signaling pathways could be identified by the analysis of the gene expression features of AMLs with non-targetable genetic alterations. The elucidation of specific molecular targets for AMLs that have a specific genetic alteration would promote personalized treatment of AMLs and improve clinical outcomes.